Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
08
04
2019
revised:
11
06
2019
accepted:
26
07
2019
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
Hyperinsulinemia, high insulin-like growth factor 1 (IGF1) levels, and low IGF binding protein 1 (IGFBP1) levels have been implicated in the relationship between obesity and increased risk of colorectal cancer (CRC). However, it remains inconclusive whether circulating biomarkers of insulin and the IGF axis are associated with conventional adenoma and serrated polyp, the two distinct groups of CRC precursors. We prospectively examined the associations of plasma C-peptide, IGF1, IGFBP1, IGFBP3, and IGF1 to IGFBP3 ratio with conventional adenoma and serrated polyp among 11 072 women from the Nurses' Health Studies. Multivariable logistic regression was used to calculate the odds ratio (OR) per 1-SD increase in each biomarker for overall risk of conventional adenoma and serrated polyp and according to polyp feature. During 20 years of follow-up, we documented 1234 conventional adenomas and 914 serrated polyps. After adjusting for various lifestyle factors (including body mass index), higher concentrations of IGFBP1 were associated with lower risk of serrated polyp (OR = 0.84, 95% confidence interval = 0.75 to 0.95, A higher plasma level of IGFBP1 was associated with lower risk of serrated polyp. Our findings support a potential role of IGFBP1 in the serrated pathway of CRC in women.
Sections du résumé
BACKGROUND
BACKGROUND
Hyperinsulinemia, high insulin-like growth factor 1 (IGF1) levels, and low IGF binding protein 1 (IGFBP1) levels have been implicated in the relationship between obesity and increased risk of colorectal cancer (CRC). However, it remains inconclusive whether circulating biomarkers of insulin and the IGF axis are associated with conventional adenoma and serrated polyp, the two distinct groups of CRC precursors.
METHODS
METHODS
We prospectively examined the associations of plasma C-peptide, IGF1, IGFBP1, IGFBP3, and IGF1 to IGFBP3 ratio with conventional adenoma and serrated polyp among 11 072 women from the Nurses' Health Studies. Multivariable logistic regression was used to calculate the odds ratio (OR) per 1-SD increase in each biomarker for overall risk of conventional adenoma and serrated polyp and according to polyp feature.
RESULTS
RESULTS
During 20 years of follow-up, we documented 1234 conventional adenomas and 914 serrated polyps. After adjusting for various lifestyle factors (including body mass index), higher concentrations of IGFBP1 were associated with lower risk of serrated polyp (OR = 0.84, 95% confidence interval = 0.75 to 0.95,
CONCLUSIONS
CONCLUSIONS
A higher plasma level of IGFBP1 was associated with lower risk of serrated polyp. Our findings support a potential role of IGFBP1 in the serrated pathway of CRC in women.
Identifiants
pubmed: 32328558
doi: 10.1093/jncics/pkz056
pii: pkz056
pmc: PMC7050032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkz056Informations de copyright
© The Author(s) 2019. Published by Oxford University Press.
Références
Clin Endocrinol (Oxf). 2018 Feb;88(2):333-340
pubmed: 29044573
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5
pubmed: 15824155
Am J Clin Nutr. 2018 Aug 1;108(2):388-397
pubmed: 30101328
Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):581-6
pubmed: 12050100
Gastroenterology. 2012 Sep;143(3):844-857
pubmed: 22763141
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):593-7
pubmed: 17372257
Gastroenterology. 2005 Aug;129(2):464-75
pubmed: 16083703
Trends Endocrinol Metab. 2009 May;20(4):153-62
pubmed: 19349193
Nat Rev Cancer. 2004 Jul;4(7):505-18
pubmed: 15229476
Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):862-7
pubmed: 12223430
Gastroenterology. 2010 Nov;139(5):1497-502
pubmed: 20633561
Growth Horm IGF Res. 2000 Apr;10 Suppl A:S28-9
pubmed: 10984282
Gut. 2015 Jun;64(6):929-36
pubmed: 25399542
Am J Epidemiol. 2008 Mar 15;167(6):653-66
pubmed: 18230679
Br J Nutr. 2012 Nov 28;108(10):1889-96
pubmed: 22264926
J Clin Endocrinol Metab. 2008 Dec;93(12):4867-72
pubmed: 18796514
Cancer Causes Control. 2013 Oct;24(10):1837-47
pubmed: 23846284
Int J Obes (Lond). 2012 Mar;36(3):440-7
pubmed: 21673650
Cancer Causes Control. 2003 Feb;14(1):65-74
pubmed: 12708727
Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330
pubmed: 22710576
J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600
pubmed: 11018095
Diabet Med. 2013 Jul;30(7):803-17
pubmed: 23413806
Carcinogenesis. 1997 Nov;18(11):2127-32
pubmed: 9395212
J Clin Endocrinol Metab. 2007 Apr;92(4):1319-25
pubmed: 17264182
Cancer Causes Control. 2010 Jan;21(1):1-10
pubmed: 19774471
J Clin Oncol. 2009 Jan 10;27(2):165-7
pubmed: 19064959
J Biol Chem. 2002 Mar 22;277(12):9889-95
pubmed: 11784721
Nat Rev Cancer. 2004 Aug;4(8):579-91
pubmed: 15286738
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1471-7
pubmed: 20501760
Am J Epidemiol. 1997 Jun 1;145(11):970-6
pubmed: 9169905
BMC Cancer. 2012 Sep 05;12:389
pubmed: 22950808
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Nat Rev Cancer. 2014 May;14(5):329-41
pubmed: 24722429
J Natl Cancer Inst. 2002 Jul 3;94(13):972-80
pubmed: 12096082
Endocr Relat Cancer. 2007 Sep;14(3):721-32
pubmed: 17914102
N Engl J Med. 2013 Dec 12;369(24):2355
pubmed: 24350357
Am J Public Health. 2016 Sep;106(9):1573-81
pubmed: 27459450
Cancer Epidemiol. 2015 Apr;39(2):160-5
pubmed: 25592235
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2310-7
pubmed: 19661090
J Endocrinol. 2002 Oct;175(1):19-31
pubmed: 12379487
Cancer Prev Res (Phila). 2017 May;10(5):270-278
pubmed: 28325827
Mol Biol Rep. 2013 May;40(5):3583-90
pubmed: 23269623
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2076-81
pubmed: 16172212
Cancer Epidemiol. 2015 Dec;39(6):1026-35
pubmed: 26388613
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):750-5
pubmed: 16614119
Metabolism. 2015 Oct;64(10):1324-33
pubmed: 26169471
Int J Cancer. 2010 Apr 1;126(7):1702-15
pubmed: 19810099
Gastroenterology. 2018 Aug;155(2):355-373.e18
pubmed: 29702117